Fennec Pharmaceuticals Inc. (FENC) Financial Statements (2026 and earlier)

Company Profile

Business Address PO BOX 13628
RESEARCH TRIANGLE PARK, NC 27709
State of Incorp. BC
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)
Annual | Quarterly

3/31/2026
MRQ
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments36,78826,63413,26923,77421,10030,344
Cash and cash equivalent36,78826,63413,26923,77421,10030,344
Receivables(5,904)(3,803)(300)   
Prepaid expense3,7383,0802,5757701,034797
Other current assets1,7314664463253276
Other undisclosed current assets30,69017,74711,2702,121  
Total current assets:67,04344,12426,85826,72822,38731,417
Noncurrent Assets
Long-term investments and receivables2,791     
Accounts and financing receivable, after allowance for credit loss2,791     
Other noncurrent assets7172,438    
Other undisclosed noncurrent assets  (1,616)621127 
Total noncurrent assets:3,508822621127 
TOTAL ASSETS:70,55144,94626,86426,93922,41431,417
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities10,2706,6697,5324,6091,6542,347
Accounts payable4,6353,2413,7782,3907771,571
Accrued liabilities5,6353,4283,7542,219877776
Deferred revenue248248    
Other undisclosed current liabilities  221   
Total current liabilities:10,5186,9197,5534,6091,6542,347
Noncurrent Liabilities
Liabilities, other than long-term debt24,56124,5612   
Deferred revenue24,56124,561    
Operating lease, liability   2   
Other undisclosed noncurrent liabilities  19,33830,93124,8994,988 
Total noncurrent liabilities:24,56143,89930,93324,8994,988 
Total liabilities:35,07950,81838,48629,5086,6422,347
Equity
Equity, attributable to parent35,472(5,872)(11,622)(2,569)15,77229,070
Common stock189,906145,608144,307142,591140,801140,733
Additional paid in capital73,74566,95862,07356,79753,21449,234
Accumulated other comprehensive income1,2431,2431,2431,2431,2431,243
Accumulated deficit(229,422)(219,681)(219,245)(203,200)(179,486)(162,140)
Total equity:35,472(5,872)(11,622)(2,569)15,77229,070
TOTAL LIABILITIES AND EQUITY:70,55144,94626,86426,93922,41431,417

Income Statement (P&L) ($ in thousands)
Annual | Quarterly

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Revenues44,64247,53821,252   
Cost of revenue(773)(517)(1,259)(86)  
Cost of product and service sold (773)(517)(1,259)(86)  
Other undisclosed gross profit    1,535  
Gross profit:43,86947,02119,9931,449  
Operating expenses(50,924)(44,970)(32,764)(24,038)(17,223)(18,055)
Other undisclosed operating income773517   170
Operating income (loss):(6,282)2,568(12,771)(22,589)(17,223)(17,885)
Nonoperating expense(3,353)(2,639)(3,274)(1,125)(123)(224)
Investment income, nonoperating7871,682 1955487
Interest and debt expense(2,022)(4,069)   (402)
Loss from continuing operations before equity method investments, income taxes:(11,657)(4,140)(16,045)(23,714)(17,346)(18,511)
Other undisclosed income from continuing operations before income taxes2,0224,069    
Loss from continuing operations before income taxes:(9,635)(71)(16,045)(23,714)(17,346)(18,511)
Income tax expense (106)(365)    
Other undisclosed loss from continuing operations      
Loss from continuing operations:(9,741)(436)(16,045)(23,714)(17,346)(18,511)
Loss before gain (loss) on sale of properties:✕✕✕✕✕(17,346)(18,511)
Other undisclosed net loss      
Net loss:(9,741)(436)(16,045)(23,714)(17,346)(18,511)
Other undisclosed net income attributable to parent     402
Net loss available to common stockholders, diluted:(9,741)(436)(16,045)(23,714)(17,346)(18,109)

Comprehensive Income ($ in thousands)
Annual | Quarterly

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Net loss:(9,741)(436)(16,045)(23,714)(17,346)(18,511)
Comprehensive loss, net of tax, attributable to parent:(9,741)(436)(16,045)(23,714)(17,346)(18,511)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: